Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

X
Trial Profile

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GEN 3014 (Primary) ; Daratumumab
  • Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Genmab A/S
  • Most Recent Events

    • 12 Jan 2024 Planned End Date changed from 1 Feb 2029 to 31 Dec 2026.
    • 12 Dec 2023 Results (N=11, As of May 5, 2023, median age, 66 years; range, 56-75 ) assessing the preliminary antitumor activity, safety, tolerability, and pharmacokinetics/pharmacodynamics of GEN3014 were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 02 Nov 2023 According to a Genmab media release, data from this study will be presented at the 65thAnnual Meeting and Exposition of the American Society of Hematology (ASH)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top